EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study
Robert Pirker(Medical University of Vienna), Kenneth J. O’Byrne(Translational Research Institute), Joachim von Pawel(Asklepios Fachkliniken München-Gauting), Keunchil Park(The University of Texas MD Anderson Cancer Center), Anja von Heydebreck(Merck (Germany)), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Stephan Störkel(National Institutes of Health), Wilfried Eberhardt(National Center for Tumor Diseases), Maciej Krzakowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Karl-Maria Schumacher(Merck (Germany)), Ilhan Celik(Merck (Germany)), Filippo de Marinis(Carlo Forlanini Hospital), Jose R. Pereira(Ontario Institute for Cancer Research), Rodryg Ramlau(Poznan University of Medical Sciences)
Cited by 574
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Lung cancer: current therapies and new targeted treatments
|The Lancet|2016|3.3k